Phase 3 study of CPN-302: Positive topline results for post-cataract surgery drug candidateAugust 13th 2022
The companies note that data from Study CPN-302 confirm the results in the first Phase 3 study, CPN-301, and they demonstrate the clear benefits of treating patients after cataract surgery with APP13007.
Intravenous bevacizumab repackaged for intravitreal use: Making the sight-saving treatment saferAugust 10th 2022
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
The need for precision management in glaucoma moves field forwardAugust 8th 2022
Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.
High-tech, noninvasive imaging identifies early glaucomaAugust 6th 2022
Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.
Black-and-white filters optimize visualization during cataract surgeryJuly 28th 2022
While the surgeons reported that the BW filter provided higher contrast during nucleus and viscous removal and posterior capsular polishing, they subjectively reported no significant advantage of using a BW filter.
RegeneRx, HLB Therapeutics sign letter of intent for Phase 3 clinical trials in neurotrophic keratitisJuly 20th 2022
RegeneRX Biopharmaceuticals and its US joint venture partner and licensee, HLB Therapeutics, signed a letter of intent this week with a global ophthalmology contract research organization to conduct a pair of Phase 3 clinical trials simultaneously beginning in the fall in the US and Europe for patients with neurotrophic keratitis.
ASRS 2022 in review: New data on DMO, AMD presented at this year's meetingJuly 19th 2022
The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, United States, from 13-16 July, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema dominated the conversation.
Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defectsJuly 10th 2022
Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.
Intraventricular haemorrhage in first year may lead to long-term sight problemsJuly 9th 2022
Researchers at the University of Bristol, as part of a 10-year follow-up study, found that severe “brain bleeds” experienced by some babies in the first year following their birth lead to long-term sight problems.
Self-plugging microneedles may improve drug delivery in the eyeJune 27th 2022
In a recent study, investigators found preclinical evidence that this innovative, biodegradable microneedle, dip-coated with a therapeutic drug for release upon insertion into the eyeball, can also be equipped with a special hydrogel that simultaneously seals off the insertion hole.